Compare Microchip Technology Inc. (MCHP) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Microchip Technology Inc. trades at $74.15 (market cap $41.01B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: Microchip Technology Inc. is far larger — about 19.2× Recursion Pharmaceuticals Inc's market cap, and Microchip Technology Inc. pays a 2.41% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 62 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MCHP | RXRX | |
|---|---|---|
Market Cap | $41.01B | $2.14B |
Volume | 9,972,516 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $102.97 | $6.79 |
52-Week Low | $49.02 | $2.84 |
Typical Hold Time | 62 Days | 22 Days |
Enterprise Value | $46.13B | $1.66B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $78.02, down 3.99% today, amid a bearish technical signal. The company shows mixed fundamentals with strong recent earnings beats but a challenging 2025 with negative net income. Valuation metrics appear elevated with P/E of 111.06 and P/S of 8.08. Recent developments include the acquisition of Hailo and expansion of Ethernet and power portfolios targeting automotive and data center markets.
Outlook remains cautiously optimistic with analyst consensus at $110.50 (41% upside) and no sell ratings. Key opportunities include AI infrastructure demand and inventory normalization, while risks include high debt levels, competitive pressures, and semiconductor cycle volatility. The stock's performance hinges on execution of growth initiatives and market conditions.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
